About the Study
Mission
VITAL will deliver a comprehensive, clinically validated, multi-scale, multi-organ modelling platform that is driven by and can represent individual patient data acquired both in the clinic and from wearable technology. The platform will create a virtual human twin for individualised and sex-specific optimisation of medical (pharmacological) or surgical (interventional) therapy for complex, multifactorial cardiovascular disorders that have systemic impact and high risk of comorbidities of, amongst others, the kidney and brain: systemic hypertension, heart failure (with/without preserved ejection fraction) and hemodynamically complicated atrial septal defects. In the remainder of the text, these disorders are referred to as “circulation overload disorders” (CODs). User-friendly interfaces, co-created with healthcare professionals, will provide access to the technology. By the end of the project, the platform will have been validated and tested in more than 200 patients across 5 clinical studies in France and the UK.
Ambition
VITAL’s virtual human twins are personalised multi-scale computational models that have the potential to predict disease progression and treatment outcomes over a period of months to years. This technology offers the possibility of delivering optimised and cost-effective patient management strategies, surpassing current standards of clinical care.
We identified four complex CODs with significant socioeconomic repercussions, an incompletely understood interrelationship between cardiac and vascular function, renal, hormonal, and other factors (environmental, genetic, psychosocial), and different treatment options with unpredictable outcomes. Next generation virtual human twins, capable of characterising disease endophenotypes forecasting sex-specific long-term responses to surgical or medical (pharmaceutical) treatments on the cardiovascular and other organ systems, address unmet clinical needs and improve current clinical standards.